Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-U3270
Cancer Immunotherapy Market is poised to value over CAGR of over 13.8% during the forecast period 2022 to 2028. Increased acceptance of target therapies over conventional methods, the introduction of biosimilars and growing prevalence of chronic diseases like cancer are some of the key factors contributing to the growth of the market. There has been a rise in the number of research and development activities in the field of cancer immunotherapy which has resulted in the emergence of novel variants that enhance the effectiveness and efficacy of the treatment. Furthermore, the side effects of chemotherapy have led to patients opting for other treatment alternatives which has increased the demand for immunotherapy, thereby assisting in the growth of the market. Moreover, immunotherapies can be used for treating a wide range of cancer types like skin cancer, breast cancer, lung cancer, etc. Additionally, the increased expenditure on healthcare and improvements in the provision of health insurance shall boost the cancer immunotherapy market growth. However, a lack of skilled healthcare personnel and earth of awareness among the general population shall impede the market growth. The emergence of new class of drugs like histone deacetylase and monoclonal antibodies are designed in such a way that they target the receptors that ae related to myeloma and with the approval of CTLA-4 and PD-1 checkpoint inhibitors for non-small cell lung cancer and melanoma has contributed in boosting the growth of the market. Market Segmentation: By Type Monoclonal Antibodies Cancer Vaccines Checkpoint Inhibitors Immunomodulators By Cancer Type Lung Cancer Breast Cancer Colorectal Cancer Melanoma Prostate Cancer Multiple Myeloma Ovarian Cancer Head and Neck Cancer Pancreatic Cancer By End User Hospital Cancer Research Centers Clinics By Region North America Europe Asia-Pacific Latin America Middle East and Africa The market is classified into type, cancer type, end user and region. The type segment is fragmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors and immunomodulators. The monoclonal antibodies segment is anticipated to hold the largest cancer immunotherapy market share and this can be credited to a rise in the investments dedicated to the research and development of monoclonal antibodies like conjugated monoclonal antibodies, bispecific antibodies, antigen binding antibodies. These activities have led to the emergence of antibodies that have benefits such as adaptive immunity, cellular toxicity depending on the antibody and antigen specificity. Such advantages have resulted in the proliferation of the market. The immunomodulators segment is predicted to grow at a faster rate during the forecast period as they can enhance the immune system activity against tumors. Non-specific therapies like growth factors and cytokine modulators are developed to perform as agents that stimulate immunity, thereby resulting in the improvement of overall responses against tumors. The cancer type segment is divided into lung cancer, breast cancer, melanoma, colorectal cancer, prostate cancer, multiple myeloma, ovarian cancer, head and neck cancer and pancreatic cancer. The lung cancer segment is expected to lead the market owing to a rise in the number of patients diagnosed with lung cancer and the increased development of checkpoint inhibitors for curing non-small cell lung cancer. Regional Analysis: The North America region is expected to lead the global market owing toa rise in the prevalence of chronic diseases like cancer in the region, increased accessibility to advanced therapies along with the rising geriatric population. The Asia Pacific region, on the other hand, is predicted to grow at a faster rate during the forecast period and this is due to increased FDA approvals for novel drugs and therapies and rise in the number of clinical trials for introducing new drugs in countries like India and China, who are experiencing a rise in the geriatric population, thereby raising their chances of increasing the patient pool. Competitive Landscape: The key market players involved are F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc., Astrazeneca plc. FutureWise Key Takeaways: Growth prospects SWOT analysis Key market trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global cancer immunotherapy market by product, by cancer type, by end user and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Increased acceptance of target therapies over conventional methods, the introduction of biosimilars and growing prevalence of chronic diseases like cancer are some of the key factors contributing to the growth of the market. There has been a rise in the number of research and development activities in the field of cancer immunotherapy which has resulted in the emergence of novel variants that enhance the effectiveness and efficacy of the treatment. Furthermore, the side effects of chemotherapy have led to patients opting for other treatment alternatives which has increased the demand for immunotherapy, thereby assisting in the growth of the market. Moreover, immunotherapies can be used for treating a wide range of cancer types like skin cancer, breast cancer, lung cancer, etc.
Additionally, the increased expenditure on healthcare and improvements in the provision of health insurance shall boost the cancer immunotherapy market growth. However, a lack of skilled healthcare personnel and earth of awareness among the general population shall impede the market growth. The emergence of new class of drugs like histone deacetylase and monoclonal antibodies are designed in such a way that they target the receptors that ae related to myeloma and with the approval of CTLA-4 and PD-1 checkpoint inhibitors for non-small cell lung cancer and melanoma has contributed in boosting the growth of the market.
Market Segmentation:
By Type
By Cancer Type
By End User
By Region
The market is classified into type, cancer type, end user and region. The type segment is fragmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors and immunomodulators. The monoclonal antibodies segment is anticipated to hold the largest cancer immunotherapy market share and this can be credited to a rise in the investments dedicated to the research and development of monoclonal antibodies like conjugated monoclonal antibodies, bispecific antibodies, antigen binding antibodies. These activities have led to the emergence of antibodies that have benefits such as adaptive immunity, cellular toxicity depending on the antibody and antigen specificity. Such advantages have resulted in the proliferation of the market. The immunomodulators segment is predicted to grow at a faster rate during the forecast period as they can enhance the immune system activity against tumors. Non-specific therapies like growth factors and cytokine modulators are developed to perform as agents that stimulate immunity, thereby resulting in the improvement of overall responses against tumors. The cancer type segment is divided into lung cancer, breast cancer, melanoma, colorectal cancer, prostate cancer, multiple myeloma, ovarian cancer, head and neck cancer and pancreatic cancer. The lung cancer segment is expected to lead the market owing to a rise in the number of patients diagnosed with lung cancer and the increased development of checkpoint inhibitors for curing non-small cell lung cancer.
Regional Analysis:
The North America region is expected to lead the global market owing toa rise in the prevalence of chronic diseases like cancer in the region, increased accessibility to advanced therapies along with the rising geriatric population. The Asia Pacific region, on the other hand, is predicted to grow at a faster rate during the forecast period and this is due to increased FDA approvals for novel drugs and therapies and rise in the number of clinical trials for introducing new drugs in countries like India and China, who are experiencing a rise in the geriatric population, thereby raising their chances of increasing the patient pool.
Competitive Landscape:
The key market players involved are F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc., Astrazeneca plc.
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2.Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Cancer Immunotherapy Market, By Type Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 7.1 Monoclonal Antibodies 7.2 Cancer Vaccines 7.3 Checkpoint Inhibitors 7.4 Immunomodulators 8. Cancer Immunotherapy Market, By Cancer Type Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 8.1 Lung Cancer 8.2 Breast Cancer 8.3 Colorectal Cancer 8.4 Melanoma 8.5 Prostate Cancer 8.6 Multiple Myeloma 8.7 Ovarian Cancer 8.8 Head and Neck Cancer 8.9 Pancreatic Cancer 9. Cancer Immunotherapy Market, By End User Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 9.1 Hospital 9.2 Cancer Research Centers 9.3 Clinics 10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Mn) Analysis By Country, 2016-2020 10.2.1. U.S. 10.2.2. Canada 10.2.3. Mexico 10.2.4. Rest of North America 10.3 Market Size (USD Mn) Forecast for North America 2022-2028 11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4 Market Size (US$ Mn) Forecast for Latin America 2022-2028 12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5 Switzerland 12.2.6. Spain 12.2.7. Russia 12.2.8. Poland 12.2.9. Rest of Western Europe 12.3 Market Size (US$ Mn) Forecast for Europe 2022-2028 13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 13.2.1 Japan 13.2.2 China 13.2.3 Singapore 13.2.4 Korea 13.2.5 India 13.2.6 Australia and New Zealand 13.2.7 ASEAN 13.2.8 Rest of Asia Pacific 13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 14.2.1 GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3 Market Size (US$ Mn) Forecast for MEA 2022-2028 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1 F. Hoffmann-La Roche AG 15.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2 Advaxis Inc. 15.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3 Merck & Co. Inc. 15.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4 Eli Lilly and Company 15.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Bristol-Myers Squibb Company 15.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Pfizer Inc. 15.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7 Novartis AG 15.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8 Bayer AG 15.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9 Immunomedics Inc. 15.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10 Astrazeneca plc. 15.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 16. Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. Competitive Intelligence and Competitive Matrix 17.1 Competitive Intelligence 17.2 Competitive Matrix 18. Major Deals and Strategic Alliances Analysis 18.1 Joint ventures 18.2 Mergers and acquisitions 18.3 Licensing and partnerships 18.4 Technology Collaborations 18.5 Strategic Divestments 18.6 Market Entry Strategies 19. Relevant Case Studies and Latest News Updates 20. Research Sources and List of Primary Contacts of this Study 21. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics